Shares of Hemab Therapeutics Holdings Inc (Symbol: COAG) surged above the average analyst 12-month target price of $50.00, reaching $50.39 per share in recent trading. This movement prompts an evaluation of whether analysts will adjust their target prices or downgrade the stock, considering the underlying business developments that may be driving the stock price higher.
Currently, there are five analysts covering Hemab Therapeutics, contributing to a price target range from a low of $46.00 to a high of $55.00, with a standard deviation of $3.674. Notably, five analysts rate the stock as a “Strong Buy” and one as a “Hold,” resulting in an average rating of 1.33, indicating a consensus towards bullish sentiment.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
